Extra stitches may cut leak risk after rectal cancer surgery
NCT ID NCT07346534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding extra stitches around the surgical connection in laparoscopic low rectal cancer surgery can reduce the risk of dangerous leaks. About 300 adults with low rectal cancer will be assigned to either standard surgery or surgery with reinforced stitching. The goal is to see if the reinforced method leads to fewer complications and better recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 18 and 85 years. 2. Diagnosed with low rectal adenocarcinoma located within 7 cm from the anal verge by colonoscopy and biopsy. 3. Scheduled for elective laparoscopic low anterior resection (Dixon procedure). 4. Clinical stage I-III (based on preoperative imaging, e.g., MRI/CT) without distant metastasis. 5. Adequate organ function (hematologic, hepatic, renal) to tolerate surgery. 6. Provided written informed consent and willing to comply with study procedures and follow-up. Exclusion Criteria: 1. Presence of synchronous distant metastases or other malignancies. 2. History of prior pelvic radiotherapy or major pelvic surgery. 3. Severe uncontrolled comorbidities (e.g., severe cardiovascular, respiratory, hepatic or renal insufficiency). 4. Emergency surgery indication (e.g., bowel obstruction, perforation). 5. Pregnancy or breastfeeding. 6. Known allergy or contraindication to anesthesia or surgical materials used. 7. Participation in another interventional clinical trial within the last 3 months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai Tenth People's Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab test tell which chemo works for colon cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days